Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03394066 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Mechanism of Non-invasive Magnetic Stimulation

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Dec 31, 2026 → Dec 31, 2028
See other at-risk trials from National Institute on Drug Abuse (NIDA)

Record History

The 50 most recent of 683 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Minor Re-verified, no change to tracked fields
  2. Minor Re-verified, no change to tracked fields
  3. Minor Re-verified, no change to tracked fields
  4. Minor Re-verified, no change to tracked fields
  5. Minor Re-verified, no change to tracked fields
Show 10 earlier versionsHide 10 earlier versions
  1. Minor Eligibility criteria expanded, about 50 words
  2. Minor 9 versions Re-verified since Jul 22, 2026, no change to tracked fieldsv669-v677
  1. Notable Primary and study completion pushed from Dec 31, 2026 to Dec 31, 2028 Enrollment increased: 70 → 95 participants · Eligibility criteria revisedv668 Show 2 more changesShow less
    • Enrollment increased: 70 → 95 participants
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  2. Notable Primary and study completion dates: Dec 31, 2026 to Dec 31, 2028 Enrollment target: 70 to 95v667 Show 1 more changeShow less
    • Enrollment target: 70 to 95
  3. Minor 4 versions Re-verified since May 28, 2026, no change to tracked fieldsv663-v666
  4. Minor Eligibility criteria expanded, about 1 wordv662 See this version in full on ClinicalTrials.gov ↗
  5. Minor Eligibility criteria shortened, about 38 wordsv661 See this version in full on ClinicalTrials.gov ↗
  6. Minor 7 versions Re-verified since Feb 26, 2026, no change to tracked fieldsv654-v660
  7. Minor Eligibility criteria expanded, about 4 wordsv653 See this version in full on ClinicalTrials.gov ↗
  8. Minor 7 versions Re-verified since Aug 19, 2025, no change to tracked fieldsv646-v652
  9. Minor Study Status, Eligibilityv645
  10. Minor 11 versions Re-verified since May 3, 2025, no change to tracked fieldsv634-v644
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Background: Transcranial magnetic stimulation (TMS) is form of non-invasive brain stimulation. It is approved to treat depression. TMS may help decrease drug craving. It is important to understand how TMS affects the brain. Such a better understanding would help to design ways to treat drug addiction. Objectives: To learn how TMS affects the brain when it stimulates an area in the front of the brain. Also, to see how the stimulation affects the area stimulated and other connected areas. Eligibility: Healthy, right-handed adults ages 18-60 who are non-drug users. Design: Participants will be screened under protocol 06-DA-N415. Participants will have at least 3 visits. The first visit will last about 3 hours. All other visits will last up to 6 hours. Participants cannot use drugs or alcohol at least 24 hours before a visit. They cannot have more than half a cup of a caffeinated drink at least 12 hours before a visit. Each visit will include a brief medical history update, urine test for drugs and pregnancy (if female), a breath test for alcohol and smoking, and questionnaires. Participants will have a TMS orientation visit. A wire coil will be placed on the head. An electrical current will pass through the coil to create a magnetic pulse that stimulates the brain. The other visits will include 2 sessions of TMS-MRI. Participants will lie on a table that slides into a cylinder. The TMS coil and the MRI coil will be placed over the head. Pictures will be taken of the brain with and without stimulation. Participants will complete a questionnaire about how they feel before and after each TMS session and in a follow-up call 1-3 days after their last session.
Trial Details
NCT Number NCT03394066
Lead Sponsor National Institute on Drug Abuse (NIDA)
Conditions Healthy Volunteers
Enrollment 95 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov